about
Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and societyTranslating biotechnology to knowledge-based innovation, peace, and development? Deploy a Science Peace Corps--an open letter to world leadersFrequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirinCrowd-funded micro-grants for genomics and "big data": an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropyWhat Role for Law, Human Rights, and Bioethics in an Age of Big Data, Consortia Science, and Consortia Ethics? The Importance of Trustworthiness.Toward more transparent and reproducible omics studies through a common metadata checklist and data publicationsDesigning a post-genomics knowledge ecosystem to translate pharmacogenomics into public health actionTowards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)Opportunities and challenges for the life sciences communityReady to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy.A Delphi Technology Foresight Study: Mapping Social Construction of Scientific Evidence on Metagenomics Tests for Water Safety.Big data and ethics review for health systems research in LMICs: understanding risk, uncertainty and ignorance -- and catching the black swans?Personalized medicine beyond genomics: alternative futures in big data-proteomics, environtome and the social proteome.Precision Nutrition 4.0: A Big Data and Ethics Foresight Analysis--Convergence of Agrigenomics, Nutrigenomics, Nutriproteomics, and Nutrimetabolomics.Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications.Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.All the post-genomic world is a stage: the actors and narrators required for translating pharmacogenomics into public healthThe United States of America and scientific researchPolicy and data-intensive scientific discovery in the beginning of the 21st century.Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder.Fasidotril Eli Lilly.Aripiprazole (Otsuka Pharmaceutical Co).Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine.Standardization and omics science: technical and social dimensions are inseparable and demand symmetrical studyCrowdfunding 2.0: the next-generation philanthropy: a new approach for philanthropists and citizens to co-fund disruptive innovation in global healthPharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health.Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.Evaluation of Nine Consensus Indices in Delphi Foresight Research and Their Dependency on Delphi Survey Characteristics: A Simulation Study and Debate on Delphi Design and InterpretationEnd of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patientsShifting emphasis from pharmacogenomics to theragnostics.Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.Mapping translational research in personalized therapeutics: from molecular markers to health policy.Evidence-based management of nutrigenomics expectations and ELSIs.Genome-environment interactions and prospective technology assessment: evolution from pharmacogenomics to nutrigenomics and ecogenomics.Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).Steering vaccinomics innovations with anticipatory governance and participatory foresight.How Healthcare Can Refocus on Its Super-Customers (Patients, n =1) and Customers (Doctors and Nurses) by Leveraging Lessons from Amazon, Uber, and Watson.
P50
Q24289220-EAD03139-D027-4BDD-B6AE-31F393A0D1C6Q27003942-36C4D2C2-83E4-4BDC-BB2A-B8546E9E9F23Q28212922-10115899-7209-411A-90B4-AA496FE9A47BQ28603157-4C1E015F-7548-4584-A17E-404BE5600E7AQ28608097-B94631B3-2850-4CA1-B5B9-A9D76BA57315Q28660033-A3835118-8DB2-42AE-8FF4-95D8B0A6F4FAQ28706810-BF517C1D-F34D-42E4-B970-58BD0CCB0905Q28730530-CFB64A3B-7A55-4954-A12E-F924DE0DF8BFQ28731358-D619055A-76F4-4A5E-94A8-E739EE7571A0Q30062193-67F349F6-DC03-4A0C-AE9D-81072BC477A8Q30388450-1FA01770-3BB6-4659-8679-C822A5CED65EQ30755714-5D9A97BB-EDFC-4351-A4A5-ADB31BE2F034Q31030776-E2A4E246-19BE-40A8-A6C2-8B8D9EF5108BQ31037965-19F030E5-B635-4CD2-A034-233DE95743A9Q31116777-039BAD15-7AB3-4295-B5CA-2A590ACC0DB7Q33232404-34109F8B-B1D7-4639-97C1-773E56D7E1F2Q33553392-D02044A2-D82A-461C-8B41-3087E10497B3Q33680982-9D88AB2B-1252-4E7C-BC61-48FCDD8D915FQ33866156-4870EF5D-2240-479D-A36B-7E00385A0822Q34543502-98373976-AD5D-4E13-9C25-1DF5D8C7AD2BQ34649070-86AACEE2-4BEC-45E5-B2F5-A489C34B1A2DQ34675478-5E0833B7-AE4D-47C9-97B8-6555FE6FA8A2Q34778689-1941870C-9748-4957-9F24-4AE54130715CQ35082733-BD0C307E-D3BE-45E3-B44C-CD6C984FC8DDQ35192228-C6BA0097-25D5-4FBD-8996-3123B10B07E4Q35668121-8B5F6BD2-00BD-4A9B-9561-51E672D92AF9Q35690458-A3C68963-DE01-49CF-8EF4-3476D9AE2B88Q35690469-3F3B0827-A7DB-471B-A85E-AC26C7DAE949Q35745080-0272FD1D-D444-4B2C-A0E7-2B53163878A6Q35917987-A68B4377-2D9B-4780-A25C-4A40711525A5Q36024636-BA80AD68-8147-48D3-B24A-66CEE0D21111Q36561637-8574648C-F6B6-4157-B78E-D322BA4A9743Q36690255-A8D487E3-A9D3-4DE2-A23A-E72F7482ECB6Q36710030-9CBE72B2-AC09-4183-A582-701612A8D802Q36730634-DAF6CD59-0DFE-4420-918E-4AD176004841Q36918136-5C9163FD-C6A9-47BF-BB43-6EABB76F7E47Q37416136-1907712F-2A76-4CB2-B3DC-0102373DB3D1Q37686203-E0DA4649-CF87-442B-A39C-225213801007Q37919074-99CB7844-BF3F-4B3D-B2FB-E30ABD8DEF82Q38867059-4E988494-82D4-4641-9F7A-973D4ADC93E0
P50
description
onderzoeker
@nl
name
Vural Özdemir
@ast
Vural Özdemir
@en
Vural Özdemir
@nl
Vural Özdemir
@sl
type
label
Vural Özdemir
@ast
Vural Özdemir
@en
Vural Özdemir
@nl
Vural Özdemir
@sl
altLabel
Vural Ozdemir
@en
prefLabel
Vural Özdemir
@ast
Vural Özdemir
@en
Vural Özdemir
@nl
Vural Özdemir
@sl
P106
P214
475144782720544536271
P31
P6100
CB309E5FE8563527
P7859
viaf-475144782720544536271